March 2017

New Product - Zinbryta

Zinbryta (daclizumab) is a humanised IgG₁ monoclonal antibody that binds specifically to the alpha subunit of the interleukin-2 receptor (IL-2Rα, CD25). Immunomodulatory effects of daclizumab are believed to reduce CNS pathology in multiple sclerosis and thereby reduce the occurrence of relapses and disability progression. Zinbryta is indicated for the treatment of relapsing forms of multiple sclerosis to delay the progression of physical disability and to reduce the frequency of relapse. Zinbryta is contraindicated in patients with pre-existing hepatic disease or hepatic impairment, including ALT or AST at least 2 times the ULN at baseline, because Zinbryta could exacerbate existing liver dysfunction; and a history of autoimmune hepatitis or other autoimmune condition involving the liver. Zinbryta is available as a 150 mg/mL prefilled pen in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au